These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 35630058)

  • 1. Chronic Inflammation-A Link between Nonalcoholic Fatty Liver Disease (NAFLD) and Dysfunctional Adipose Tissue.
    Petrescu M; Vlaicu SI; Ciumărnean L; Milaciu MV; Mărginean C; Florea M; Vesa ȘC; Popa M
    Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adipokines in nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1062-79. PubMed ID: 26725002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease.
    Cimini FA; Barchetta I; Carotti S; Bertoccini L; Baroni MG; Vespasiani-Gentilucci U; Cavallo MG; Morini S
    World J Gastroenterol; 2017 May; 23(19):3407-3417. PubMed ID: 28596677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
    Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
    J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis.
    Mendez-Sanchez N; Cruz-Ramon VC; Ramirez-Perez OL; Hwang JP; Barranco-Fragoso B; Cordova-Gallardo J
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathways of nonalcoholic fatty liver disease development and progression.
    Bessone F; Razori MV; Roma MG
    Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.
    Stojsavljević S; Gomerčić Palčić M; Virović Jukić L; Smirčić Duvnjak L; Duvnjak M
    World J Gastroenterol; 2014 Dec; 20(48):18070-91. PubMed ID: 25561778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms.
    Rodríguez-Calvo R; Samino S; Girona J; Martínez-Micaelo N; Ràfols P; García-Altares M; Guaita-Esteruelas S; Junza A; Heras M; Yanes O; Correig X; Masana L
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32899418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.
    Lim S; Taskinen MR; Borén J
    Obes Rev; 2019 Apr; 20(4):599-611. PubMed ID: 30589487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Potential Therapies Targeting Inflammation in NASH.
    Albhaisi S; Noureddin M
    Front Endocrinol (Lausanne); 2021; 12():767314. PubMed ID: 34925237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.
    Polyzos SA; Kountouras J; Zavos C
    Curr Mol Med; 2009 Apr; 9(3):299-314. PubMed ID: 19355912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis.
    Tilg H
    Curr Pharm Des; 2010 Jun; 16(17):1893-5. PubMed ID: 20370678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triggering and resolution of inflammation in NASH.
    Schuster S; Cabrera D; Arrese M; Feldstein AE
    Nat Rev Gastroenterol Hepatol; 2018 Jun; 15(6):349-364. PubMed ID: 29740166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
    Cusi K
    Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.